Enveric Biosciences is a biotechnology company focused on developing innovative therapeutics aimed at improving the quality of life for patients affected by the side effects of cancer treatments and mental health disorders. The company is exploring natural compounds, particularly cannabinoids, to create new prescription medications that address unmet medical needs. Enveric's lead program, EB-003, targets difficult mental health issues such as depression, anxiety, and addiction, promoting neuroplasticity without causing hallucinations. Additionally, the company is advancing EB-002, a synthetic prodrug of psilocin, as a potential treatment for psychiatric disorders. Through its research, Enveric Biosciences aims to provide effective solutions for patients facing challenging health conditions.
MagicMed Industries Inc. is a biotechnology company based in Calgary, Canada, that specializes in developing psychedelic-derived medicinal products and consumer goods. Founded in 2020, the company focuses on creating a library of novel derivative molecules, particularly from psilocybin and other classic psychedelics such as N,N-dimethyltryptamine (DMT). Through its proprietary Psybrary, MagicMed aims to develop patented products that are intended to be more effective and safer for various psychological indications. By harnessing innovative processes and technologies, the company seeks to provide valuable solutions that traditional pharmaceutical and consumer goods companies may lack.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.